News

Whitepaper | The Future of Radiopharmaceuticals

Whitepaper | The Future of Radiopharmaceuticals

Whitepaper
The Future of Radiopharmaceuticals: Strategic Levers From Research to Clinical Application

  • Radiopharma is rapidly evolving to meet rising patient demand. Radiopharmaceutical’s unique ability to diagnose and treat is unlocking new possibilities, but the future depends on how science, industry players and healthcare companies collaborate. Discover the key strategic levers, from research to clinical application.

  • Cristiana Gameiro, Product Manager & IBA Fellow | Jean-Michel Geets, Principal Domain Expert & IBA Fellow | Louise Piron, Marketing Manager

 

Download the whitepaper

 

Source link: https://www.iba-radiopharmasolutions.com/news/iba-radiopharma-whitepaper-radiopharmaceuticals-strategic-levers/

Image
Image

About

HKCL specializes in developing and producing high-quality Positron Emission Tomography (PET) radiopharmaceuticals, such as Fluorodeoxyglucose (18F-FDG), Prostate-Specific Membrane Antigen (18F-PSMA & 68Ga-PSMA), 18F-Flutemetamol (18F-FMM), 68Ga-DOTATATE and 11C-Acetate. HKCL also expedites products and solutions in Dosimetry, Calibration Sources and Radiation Protection.

Links

Contact

Room 12 and 13, G/F, Biotech Centre 2, No.11 Science Park West Avenue, Hong Kong Science Park, Shatin, N. T.

(852) 2332 0989 / 6270 9946

(852) 2332 0979

hkcl@hkcl.com.hk

Hong Kong Cyclotron Laboratories Limited

Hong Kong Cyclotron Laboratories Limited © 2025. All Right Reserved.